IVERCOR-COVID19
Trial question
What is the role of ivermectin in patients with COVID-19 infection?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
47.0% female
53.0% male
N = 501
501 patients (237 female, 264 male).
Inclusion criteria: adult outpatients with COVID-19 positive nasal swabs within 48 hours.
Key exclusion criteria: current home oxygen use, hospitalization requirement for COVID-19 at the time of diagnosis, or a history of hospitalization for COVID-19.
Interventions
N=250 ivermectin (a total dosage of 24-48 mg PO, based on weight).
N=251 placebo (equivalent number of matching placebo tablets).
Primary outcome
Hospitalization
5.6%
8.4%
8.4 %
6.3 %
4.2 %
2.1 %
0.0 %
Ivermectin
Placebo
No significant
difference ↔
No significant difference in hospitalization (5.6% vs. 8.4%; OR 0.65, 95% CI 0.32 to 1.31).
Secondary outcomes
No significant difference in all-cause mortality (1.6% vs. 1.2%; OR 1.34, 95% CI 0.3 to 6.07).
No significant difference in invasive mechanical ventilation (1.6% vs. 1.2%; OR 1.34, 95% CI 0.3 to 6.07).
No significant difference in dialysis (0.4% vs. 0.4%; OR 1, 95% CI 0.06 to 16.14).
Safety outcomes
No significant differences in dialysis, adverse events, or all-cause mortality.
Significant difference in time to invasive mechanical ventilation (5.25 days vs. 10 days).
Conclusion
In adult outpatients with COVID-19 positive nasal swabs within 48 hours, ivermectin was not superior to placebo with respect to hospitalization.
Reference
Julio Vallejos, Rodrigo Zoni, María Bangher et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021 Jul 2;21(1):635.
Open reference URL